AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1

AZD3759 is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) on the basis of gefitinib and has been proven to enter the central nervous system. Although the promising antitumor effects of AZD3759 on non-small cell lung cancer (NSCLC) have been demonstrated in clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ruing, Yin, Wei, Yu, Qingqing, Mao, Yanjiao, Deng, Qinghua, Zhang, Ke, Ma, Shenglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805903/
https://www.ncbi.nlm.nih.gov/pubmed/34738874
http://dx.doi.org/10.1080/21655979.2021.2001238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805903/
https://www.ncbi.nlm.nih.gov/pubmed/34738874
http://dx.doi.org/10.1080/21655979.2021.2001238

Ejemplares similares